SCHEMBL4149735

SCHEMBL4149735

Cc1cccc(NC(=O)c2c(NC(=O)c3ccncc3)sc3c2CCC(C(C)(C)C)C3)c1

nearest known ligand 0.70

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.70
PDE4B Q07343 2/20 0.70
KMT2A Q03164 2/20 0.70
PDE4D Q08499 1/20 0.70
POLB P06746 1/20 0.57
THRB P10828 1/20 0.56
TP53 P04637 2/20 0.55
MEN1 O00255 1/20 0.52
NPC1 O15118 1/20 0.52
ALDH1A1 P00352 1/20 0.52
HPGD P15428 1/20 0.52
RAB9A P51151 1/20 0.52
L3MBTL1 Q9Y468 1/20 0.52
GAA P10253 1/20 0.52
BLM P54132 1/20 0.51
SMN1; SMN2 Q16637 1/20 0.51
ANO1 Q5XXA6 2/20 0.50
LMNA P02545 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21346962 0.84 MAPT (0.81) MAPTPDE4BKMT2APDE4DPOLB
SCHEMBL21260642 0.83 KMT2A (0.83) MAPTPDE4BKMT2APDE4DPOLB
SCHEMBL918679 0.83 MAPT (0.67) MAPTPDE4BKMT2APOLBTHRB
SCHEMBL21347427 0.82 MAPT (1.00) MAPTPDE4BKMT2APDE4DPOLB
SCHEMBL21346802 0.82 MAPT (1.00) MAPTPDE4BKMT2APDE4DPOLB
SCHEMBL4154493 0.82 MAPT (0.72) MAPTPDE4BKMT2APDE4DPOLB
SCHEMBL29404234 0.79 POLB (0.49) MAPTPDE4BKMT2APOLBTHRB
SCHEMBL918990 0.76 MAPT (0.77) MAPTPDE4BKMT2APDE4DPOLB
SCHEMBL21260640 0.75 MAPT (0.81) MAPTPDE4BKMT2APDE4DPOLB
SCHEMBL20340283 0.75 MAPT (0.96) MAPTKMT2APOLBTHRBTP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090143411-A1 Thiophens and Their Use as Anti-Tumor Agents COMPASS PHARMACEUTICALS LLC (US) 2009-06-04 US claimed
EP-1802634-A2 THIOPHENS AND THEIR USE AS ANTI-TUMOR AGENTS Compass Pharmaceuticals LLC (US) 2007-07-04 EP claimed
WO-2006044826-A2 THIOPHENS AND THEIR USE AS ANTI-TUMOR AGENTS COMPASS PHARMACEUTICALS LLC (US) 2006-04-27 WO claimed
US-20090143411-A1 Thiophens and Their Use as Anti-Tumor Agents COMPASS PHARMACEUTICALS LLC (US) 2009-06-04 US disclosed
EP-1802634-A2 THIOPHENS AND THEIR USE AS ANTI-TUMOR AGENTS Compass Pharmaceuticals LLC (US) 2007-07-04 EP disclosed
WO-2006044826-A2 THIOPHENS AND THEIR USE AS ANTI-TUMOR AGENTS COMPASS PHARMACEUTICALS LLC (US) 2006-04-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090143411-A1 Thiophens and Their Use as Anti-Tumor Agents TP53, BRDT, VHL MAPT 1629/4885PDE4B 2294/4885KMT2A 3189/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.